Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
published in: Hematological Oncology
date of publication: 2020-02-13
main subject: dexamethasone, ibrutinib
Cites articles 27
- 2018-09-01
- 2018-09-04
- 2017-03-20
- 2006-04-01
Date
Title
Article - wd:Q89694000